ICAM-1 was expressed in 0.3% of CD3+ T cells overall, and in tumour and stromal compartments in 0.5% (range 0.0–61.1%) and 0.3% (range 0.0–50.4%) of CD3+ T cells respectively. Here, ICAM1 is linked to neoplasm.